IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI CO LTD has a total of 17 patent applications. Its first patent ever was published in 2015. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are HANGZHOU SUMGEN BIOTECH CO LTD, ICELL GENE THERAPEUTICS LLC and ABCLON INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 6 | |
#2 | EPO (European Patent Office) | 4 | |
#3 | WIPO (World Intellectual Property Organization) | 4 | |
#4 | China | 3 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Microorganisms | |
#5 | Fermentation | |
#6 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Tian Wenzhi | 16 |
#2 | Li Song | 13 |
#3 | Jing Deqiang | 4 |
#4 | Chen Dianze | 1 |
Publication | Filing date | Title |
---|---|---|
WO2020114355A1 | Recombinant protein targeting pd-l1 and vegf | |
WO2020029982A1 | Recombinant bifunctional protein targeting cd47 and her2 | |
CN111303295A | Recombinant chimeric membrane protein cell strain and application thereof | |
CN111278865A | Novel recombinant fusion proteins, their preparation and use | |
CN110300766A | Novel recombination bifunctional fusion proteins and its preparation method and application | |
US2018141986A1 | Recombinant bi-functional fusion protein and preparation and application therefor | |
EP3122783A1 | Novel recombinant bi-functional fusion proteins, preparation and use thereof |